Eosinophilic asthma is a subtype of asthma characterized by high levels of eosinophils, a type of white blood cell that causes airway inflammation. It accounts for approximately 50% of all severe asthma cases. There is a significant clinical need for advanced therapies as current treatment options, such as corticosteroids, may be ineffective for some patients. The growing focus on targeted biologics, including interleukin inhibitors like mepolizumab and benralizumab, is expected to drive market growth in the coming years. Advancements in eosinophilic asthma therapeutics aim to improve patient outcomes and address the limitations of existing treatments.
Major companies involved in the eosinophilic asthma pipeline drugs market include AstraZeneca, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., and others.
Leading drugs currently in the pipeline include Benralizumab, Dexpramipexole Dihydrochloride, and others.
The rising cases of severe asthma, unmet clinical needs, and increased investment in advanced biologics targeting eosinophil-driven inflammation are driving significant growth in the eosinophilic asthma drug pipeline.
The Eosinophilic Asthma Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into eosinophilic asthma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for eosinophilic asthma. The eosinophilic asthma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The eosinophilic asthma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with eosinophilic asthma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to eosinophilic asthma.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Eosinophilic asthma is a severe form of asthma characterized by elevated eosinophil levels—a type of white blood cell—in the lungs. It occurs due to an overactive immune response, leading to airway inflammation and breathing difficulties. This subtype often develops in adulthood and is not typically triggered by allergens, unlike other asthma types.
Eosinophilic asthma treatments focus on reducing inflammation and managing symptoms. Biologic therapies, such as monoclonal antibodies, target eosinophils directly. Corticosteroids, both inhaled and oral, help control inflammation. Personalized treatment plans are essential, often involving regular monitoring and adjustments to maintain symptom control and prevent exacerbations.
Eosinophilic asthma accounts for about 50% of severe asthma cases. Eosinophilia, or high eosinophil levels, affects 19.6 percent of asthma patients worldwide. In the United States, the prevalence is 18.5 percent, while it is 16 percent in the United Kingdom and 20.7 percent in Spain. In India, eosinophilia is observed in 58% of bronchial asthma patients.
This section of the report covers the analysis of eosinophilic asthma drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total eosinophilic asthma clinical trials.
The drug molecule categories covered under the eosinophilic asthma pipeline analysis include monoclonal antibodies, small molecules, immunomodulators, oligonucleotides, peptides, and others. The eosinophilic asthma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for eosinophilic asthma.
The EMR report for the eosinophilic asthma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed eosinophilic asthma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in eosinophilic asthma clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for eosinophilic asthma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of eosinophilic asthma drug candidates.
Benralizumab is a monoclonal antibody that targets the IL-5 receptor, leading to the rapid depletion of eosinophils, which helps reduce asthma exacerbations. It is being evaluated in the Benralizumab Airway Remodeling Study, sponsored by AstraZeneca, to assess its impact on structural changes and lung function in patients with severe eosinophilic asthma. This Phase IV study will track outcomes over 48 weeks in patients who are unresponsive to standard asthma therapies.
Dexpramipexole, sponsored by Areteia Therapeutics, is currently in Phase III development to assess its efficacy and safety in treating severe eosinophilic asthma. This oral small molecule works by inhibiting eosinophil maturation in the bone marrow, reducing blood eosinophil levels. The study involves approximately 1,395 participants globally, with a 52-week treatment period and completion expected by July 2026.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Eosinophilic Asthma Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for eosinophilic asthma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into eosinophilic asthma collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share